SCHEMBL9053600

SCHEMBL9053600

C=C(C)CN1C(=O)CSC1=NNC(=S)NC

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP2D6 P10635 2/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ BLM P54132 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ GAA P10253 2/20 0.34
▸ HPGD P15428 1/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ GSK3A P49840 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ PTGS1 P23219 1/20 0.32
▸ PTGS2 P35354 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29780034 0.82 LMNA (0.49) LMNACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL9053874 0.82 LMNA (0.49) LMNACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL12186945 0.82 LMNA (0.49) LMNACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL9053194 0.82 EGFR (0.40) LMNACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL9054126 0.80 LMNA (0.36) LMNACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL9152818 0.76 ALDH1A1 (0.30) ALDH1A1MAPT
SCHEMBL9054287 0.76 ALDH1A1 (0.30) ALDH1A1MAPT
SCHEMBL9145222 0.72 MEN1 (0.32) NPSR1ALDH1A1MAPTKMT2AMEN1
SCHEMBL10814618 0.72 ALDH1A1 (0.47) LMNASMN1; SMN2NPSR1GAAHPGD
SCHEMBL9494802 0.71 ALDH1A1 (0.41) LMNANPSR1GAAALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0508955-B1 Use of 2-iminothiazolidin-4-one derivatives as new medicaments CIBA GEIGY AG (CH) 1996-06-19 — — EP claimed
EP-0508955-A1 Use of 2-iminothiazolidin-4-one derivatives as new medicaments CIBA-GEIGY AG (CH) 1992-10-14 — — EP claimed
EP-0508955-B1 Use of 2-iminothiazolidin-4-one derivatives as new medicaments CIBA GEIGY AG (CH) 1996-06-19 — — EP disclosed
US-5229405-A Rheumatic diseases CIBA-GEIGY CORPORATION (US) 1993-07-20 — — US disclosed
EP-0508955-A1 Use of 2-iminothiazolidin-4-one derivatives as new medicaments CIBA-GEIGY AG (CH) 1992-10-14 — — EP disclosed
Send feedback